In the frontline setting, FOLFIRINOX or gemcitabine plus nab-paclitaxel (Abraxane) remain standard of care options for patients with metastatic pancreatic cancer; however, as the therapies have not been compared head-to-head, data cannot inform whether one regimen is preferred over the other. Read more . . .
Optimizing first- and second-line therapy, understanding the role of maintenance therapy for patients with BRCA-positive disease, and developing improved therapeutic options for elderly patients has become a priority for research in metastatic pancreatic cancer, said Steven J. Cohen, MD, medical director of the Asplundh Cancer Pavilion, chief of the Medical Oncology and Hematology Division, and vice chair of the Department of Medical Oncology at Sidney Kimmel Cancer Center at Abington-Jefferson Health.